Generic pharmaceuticals company Padagis announced on Tuesday a new partnership with The Naloxone Project (TNP), a clinician-led, nonprofit organisation dedicated to transforming the response to the opioid crisis.
The collaboration is aimed at expanding access across the United States to generic naloxone nasal spray, providing access to a lower-cost naloxone product and TNP's expertise and tailored support.
Dr Don Stader, founder of The Naloxone Project, said: "This partnership represents a unique opportunity for the states we work with. By combining Padagis' trusted naloxone spray with our medical expertise, we're able to deliver more than a medication -- we're providing enhanced resources, support, and custom solutions to strengthen state programmes that save lives."
Esperion settles with Dr. Reddy's Laboratories on NEXLETOL and NEXLIZET generics
Mint Pharmaceuticals forms distribution partnership with Bayer Canada
Padagis collaborates with The Naloxone Project to address opioid overdose crisis
Biocon's first US manufacturing facility inaugurated in Cranbury, New Jersey
Amneal's risperidone extended-release injectable suspension approved by US FDA
First FDA acceptance to waive clinical efficacy studies for monoclonal antibody biosimilars
Coya Therapeutics wins FDA clearance to advance COYA 302 into Phase 2 ALS trial
Viatris' generic iron sucrose injection gains US FDA approval